Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 3/20 | 0.59 |
| ▸ | REN | P00797 | 1/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.49 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437874 | 0.91 | CTSC (0.49) | CTSCRENCALCRL | |
| SCHEMBL29437875 | 0.90 | NTSR2 (0.49) | CTSCRENCALCRLMME | |
| SCHEMBL29630530 | 0.90 | CTSC (0.51) | CTSCRENPSMB5CALCRLLTA4H | |
| SCHEMBL30546877 | 0.90 | CTSC (0.63) | CTSCRENPSMB5LMNATDP1 | |
| SCHEMBL29701979 | 0.90 | CTSC (0.63) | CTSCRENPSMB5LMNATDP1 | |
| SCHEMBL29702042 | 0.90 | CTSC (0.63) | CTSCRENPSMB5LMNATDP1 | |
| SCHEMBL30053097 | 0.89 | CTSC (0.57) | CTSCRENPSMB5CALCRLLMNA | |
| SCHEMBL29958630 | 0.88 | REN (0.58) | CTSCRENPSMB5MME | |
| SCHEMBL29695560 | 0.88 | CTSC (0.58) | CTSCRENCALCRLLMNATDP1 | |
| SCHEMBL31026629 | 0.87 | CTSC (0.68) | CTSCLMNATDP1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713025-A2 | DELIVERY OF DUAL PAYLOAD OF MMAF OR MMAE AND TLR7 AGONISTS | The Research Foundation for The State University of New York (US) | 2026-03-25 | — | — | EP | claimed |
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-13 | — | — | US | claimed |
| EP-4301417-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | The Research Foundation for The State University of New York (US) | 2024-01-10 | — | — | EP | claimed |
| WO-2022187809-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-09-09 | — | — | WO | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4713025-A2 | DELIVERY OF DUAL PAYLOAD OF MMAF OR MMAE AND TLR7 AGONISTS | The Research Foundation for The State University of New York (US) | 2026-03-25 | — | — | EP | disclosed |
| CN-121574191-A | Myristoyl pentapeptide-17 and preparation method and application thereof | 深圳连续制药科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4301417-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | The Research Foundation for The State University of New York (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-4201951-B1 | METHOD FOR PEPTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023117904-A1 | METHOD FOR PEPTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2023-06-29 | — | — | WO | disclosed |
| EP-4201951-A1 | METHOD FOR PEPTIDE SYNTHESIS | Bachem Holding AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| WO-2022187809-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | TLR7, TLR8, TLR9 | CTSC 1982/4885REN 4405/4885PSMB5 3309/4885 |
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | CTSC 131/4885REN 2773/4885PSMB5 3664/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | CTSC 37/4885REN 3056/4885PSMB5 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.